2013-05-012024-05-17https://scholars.lib.ntu.edu.tw/handle/123456789/690108摘要：慢性阻塞性肺疾病（COPD）是一個重大的公共衛生問題，主要是由吸煙所引起的。2004年，慢性阻塞性肺病導致每年 275 萬例死亡，佔全世界首要死亡原因第四位。在過去的 幾十年，儘管吸煙率下降，慢性阻塞性肺病所造成的死亡仍是大幅上升。慢性阻塞性肺 病無法治癒，治療只能緩解症狀。預防和開發新方法來治療慢性阻塞是迫切需要的。儘 管慢性阻塞性肺病是一種常見的疾病，而且也消耗大量的醫療開支（2005 年約 2400 萬新台幣），但是前瞻性的全國性的流行病學研究或臨床試驗是缺乏的。台灣慢性阻塞 性肺病聯盟（TCoC）是由多位胸腔科的專家所組成，他們在慢性阻塞性肺病的領域有 豐富的基礎實驗和臨床研究經驗。 TCoC 重要任務將是協助設計和進行多中心（研究者 或國際研究組織與藥廠發起的）臨床試驗，以及建立慢性阻塞性肺病患者的資料庫。中 心辦公室將提供通訊聯絡，資料庫維護和核心研究的協調窗口。 TCoC 核心設施也會將 提供臨床研究者進行候選基因的 SNP 分析。參與者需要簽署知情同意書來提供臨床資 訊，血液/血漿/血清/灌洗液存儲和基因 SNP 分析。台灣慢性阻塞性肺病聯盟有能力每 年招收大約 700-800 慢性阻塞性肺病患者（從每家醫院大約每年 100-120 例）。病人的 臨床資料會使用網路建置的系統加以收集供日後分析使用。TCoC 最終的目標是推動有 治療潛力的慢性阻塞性肺病臨床試驗，並加速治療方法發展的速度，使慢性阻塞性肺病 患者的壽命得以延長，生活品質獲得改善。<br> Abstract: Chronic obstructive pulmonary disease (COPD) is a major public health problem mainly caused by cigarette smoking. In 2004, COPD causes 2.75 million deaths annually, representing the fourth leading cause of death worldwide. Mortality due to COPD has risen sharply over the past several decades despite a major decline in smoking prevalence. There is no cure for COPD, and treatments are only moderately effective at relieving symptoms. Novel approaches for prevention and treatment of COPD are urgently needed. Although COPD is a common disease in our population and consumes a large amount of health care expenditure (about 2400 million NTD in 2005), studies regarding longitudinal, prospective nationwide epidemiology, or intervention are lacking. The participating investigators of Taiwan COPD consortium (TCoC) are specialists of pulmonary medicine who have experience in conducting bench and clinical studies of COPD. The key missions of the TCoC will be to assist the design and conduct of multi-center (investigator-initiated, industry or international research groups) clinical trials, as well as the establishment of biospecimen database of COPD patients. Central office will provide the window of communication, database maintenance and core study coordination. The core facility of TCoC will provide candidate genes SNP analysis under a collaborative clinical research. Participating subjects need to sign the informed consent for clinical data , PBMC/plasma/serum/ lavage fluids storage and gene SNP analysis. By estimation, the consortium has the ability to enroll 700-800 COPD patients per year (100-120 patients from each site per year). Core clinical information will be collected using a web based information system for future analysis. The ultimate goal for TCoC is to enable clinical trials of potential therapies for COPD and speed the development of treatments that will improve the length and quality of life for patients with COPD.慢性阻塞肺病COPD (Chronic obstructive pulmonary disease)